Key players in the global dyslipidemia drugs market are engaged in launch of new drugs for the treatment of dyslipidemia, and partnerships & collaborative agreements with other companies. These strategies of key players are likely to fuel the growth of the global dyslipidemia drugs market. A few expansion strategies adopted by players operating in the dyslipidemia drugs market are:
The report on the global dyslipidemia drugs market discussed individual strategies, followed by company profiles of providers of dyslipidemia drugs market. The ‘competitive landscape’ section has been included in the dyslipidemia drugs market report to provide readers with a dashboard view and a company market share analysis of key players operating in the global dyslipidemia drugs market.
Global Dyslipidemia Drugs Market - Segmentation
Attribute | Detail |
---|---|
Drug Class |
|
Distribution Channel |
|
Region |
|
Dyslipidemia drugs market to reach US$ 16.1 Bn by 2027
Dyslipidemia drugs market is projected to expand at a CAGR of 3.5% from 2019 to 2027
Dyslipidemia drugs market is driven by increasing prevalence of population with cholesterol and triglyceride abnormalities
The retail pharmacies segment is likely to dominate the global dyslipidemia drugs market during the forecast period
Key players in the global dyslipidemia drugs market include Shionogi & Co., Ltd., Pfizer, Inc., Merck & Co., Inc., Novartis AG, Bayer AG
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Dyslipidemia Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Dyslipidemia Drugs Market Introduction
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Dyslipidemia Drugs Market Analysis and Forecasts, 2017-2027
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Mergers & Acquisitions
5.2. Pipeline Analysis
5.3. Disease Prevalence & Incidence Rate globally with key countries
6. Global Dyslipidemia Drugs Market Analysis and Forecasts, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast by Drug Class, 2017-2027
6.3.1. Statins
6.3.2. Bile Acid Resins
6.3.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
6.3.4. Niacins
6.3.5. Others
6.4. Market Attractiveness by Drug Class
7. Global Dyslipidemia Drugs Market Analysis and Forecasts, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast by Distribution Channel, 2017-2027
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Market Attractiveness by Distribution Channel
8. Global Dyslipidemia Drugs Market Analysis and Forecasts, by Region
8.1. Key Findings
8.2. Market Value Forecast by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness by Country/Region
9. North America Dyslipidemia Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast by Drug Class, 2017-2027
9.2.1. Statins
9.2.2. Bile Acid Resins
9.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
9.2.4. Niacins
9.2.5. Others
9.3. Market Value Forecast by Distribution Channel, 2017-2027
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Value Forecast by Country, 2017-2027
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Dyslipidemia Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast by Drug Class, 2017-2027
10.2.1. Statins
10.2.2. Bile Acid Resins
10.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
10.2.4. Niacins
10.2.5. Others
10.3. Market Value Forecast by Distribution Channel, 2017-2027
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Value Forecast by Country/Sub-region, 2017-2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Dyslipidemia Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast by Drug Class, 2017-2027
11.2.1. Statins
11.2.2. Bile Acid Resins
11.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
11.2.4. Niacins
11.2.5. Others
11.3. Market Value Forecast by Distribution Channel, 2017-2027
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Market Value Forecast by Country/Sub-region, 2017-2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Dyslipidemia Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast by Drug Class, 2017-2027
12.2.1. Statins
12.2.2. Bile Acid Resins
12.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
12.2.4. Niacins
12.2.5. Others
12.3. Market Value Forecast by Distribution Channel, 2017-2027
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Market Value Forecast by Country/Sub-region, 2017-2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Dyslipidemia Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast by Drug Class, 2017-2027
13.2.1. Statins
13.2.2. Bile Acid Resins
13.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
13.2.4. Niacins
13.2.5. Others
13.3. Market Value Forecast by Distribution Channel, 2017-2027
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Market Value Forecast by Country/Sub-region, 2017-2027
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (by Tier and Size of companies)
14.2. Market Share Analysis by Company (2018)
14.3. Company Profiles
14.3.1. Pfizer
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Growth Strategies
14.3.1.3. SWOT Analysis
14.3.2. Merck & Co., Inc.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Growth Strategies
14.3.2.3. SWOT Analysis
14.3.3. Bayer AG
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Growth Strategies
14.3.3.3. SWOT Analysis
14.3.4. Mylan N.V.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Growth Strategies
14.3.4.3. SWOT Analysis
14.3.5. Amgen
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Growth Strategies
14.3.5.3. SWOT Analysis
14.3.6. AstraZeneca plc
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Growth Strategies
14.3.6.3. SWOT Analysis
14.3.7. Abbott Laboratories
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Growth Strategies
14.3.7.3. SWOT Analysis
14.3.8. Bristol-Myers Squibb Company
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Growth Strategies
14.3.8.3. SWOT Analysis
14.3.9. Novartis AG
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Growth Strategies
14.3.9.3. SWOT Analysis
14.3.10. Shionogi & Co., Ltd.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Growth Strategies
14.3.10.3. SWOT Analysis
List of Tables
Table 01: Global Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
Table 02: Global Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
Table 03: Global Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2027
Table 04: North America Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2027
Table 05: North America Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
Table 06: North America Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
Table 07: Europe Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
Table 08: Europe Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
Table 09: Europe Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
Table 10: Asia Pacific Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
Table 11: Asia Pacific Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
Table 12: Asia Pacific Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
Table 13: Latin America Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
Table 14: Latin America Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
Table 15: Latin America Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
Table 16: Middle East & Africa Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
Table 17: Middle East & Africa Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
Table 18: Middle East & Africa Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
List of Figures
Figure 01: Global Dyslipidemia Drugs Market Value (US$ Mn) Forecast, 2017-2027
Figure 02: Global Dyslipidemia Drugs Market Value Share, by Drug Class, 2018
Figure 03: Global Dyslipidemia Drugs Market Value Share, by Distribution Channel, 2018
Figure 04: Global Dyslipidemia Drugs Market Value Share, by Region, 2018
Figure 05: Global Dyslipidemia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 06: Global Dyslipidemia Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027
Figure 07: Global Dyslipidemia Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Statins, 2017-2027
Figure 08: Global Dyslipidemia Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Bile Acid Resins, 2017-2027
Figure 09: Global Dyslipidemia Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Fibric Acid and Omega-3 Fatty Acid Derivatives, 2017-2027
Figure 10: Global Dyslipidemia Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Niacins, 2017-2027
Figure 11: Global Dyslipidemia Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2017-2027
Figure 12: Global Dyslipidemia Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 13: Global Dyslipidemia Drugs Market Attractiveness Analysis, by Distribution Channel, 2019-2027
Figure 14: Global Dyslipidemia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacies, 2017-2027
Figure 15:Figure 22: Global Dyslipidemia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacies, 2017-2027
Figure 16: Global Dyslipidemia Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacies, 2017-2027
Figure 17: Global Dyslipidemia Drugs Market Value Share, by Region, 2018 and 2027
Figure 18: Global Dyslipidemia Drugs Market Attractiveness, by Region, 2019-2027
Figure 19: North America Dyslipidemia Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
Figure 20: North America Dyslipidemia Drugs Market Value Share (%) Analysis, by Country, 2018 & 2027
Figure 21: North America Dyslipidemia Drugs Market Attractiveness Analysis, by Country, 2019?2027
Figure 22: North America Dyslipidemia Drugs Market Value Share (%) Analysis, by Drug Class, 2018 & 2027
Figure 23: North America Dyslipidemia Drugs Market Attractiveness, by Drug Class, 2019?2027
Figure 24: North America Dyslipidemia Drugs Market Value Share (%) Analysis, by Distribution Channel, 2018 & 2027
Figure 25: North America Dyslipidemia Drugs Market Attractiveness, by Distribution Channel, 2019?2027
Figure 26: Europe Dyslipidemia Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2027
Figure 27: Europe Dyslipidemia Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 28: Europe Dyslipidemia Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019?2027
Figure 29: Europe Dyslipidemia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 30: Europe Dyslipidemia Drugs Market Attractiveness Analysis, by Drug Class, 2019?2027
Figure 31: Europe Dyslipidemia Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 32: Europe Dyslipidemia Drugs Market Attractiveness Analysis, by Distribution Channel, 2019?2027
Figure 33: Asia Pacific Dyslipidemia Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2027
Figure 34: Asia Pacific Dyslipidemia Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 35: Asia Pacific Dyslipidemia Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
Figure 36: Asia Pacific Dyslipidemia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 37: Asia Pacific Dyslipidemia Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027
Figure 38: Asia Pacific Dyslipidemia Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 39: Asia Pacific Dyslipidemia Drugs Market Attractiveness Analysis, by Distribution Channel, 2019-2027
Figure 40: Latin America Dyslipidemia Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2027
Figure 41: Latin America Dyslipidemia Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 42: Latin America Multiple Sclerosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
Figure 43: Latin America Dyslipidemia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 44: Latin America Dyslipidemia Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027
Figure 45: Latin America Dyslipidemia Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 46: Latin America Dyslipidemia Drugs Market Attractiveness Analysis, by Distribution Channel, 2019-2027
Figure 47: Middle East & Africa Dyslipidemia Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2027
Figure 48: Middle East & Africa Dyslipidemia Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 49: Middle East & Africa Multiple Sclerosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
Figure 50: Middle East & Africa Dyslipidemia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 51: Middle East & Africa Dyslipidemia Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027
Figure 52: Middle East & Africa Dyslipidemia Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 53: Middle East & Africa Dyslipidemia Drugs Market Attractiveness Analysis, by Distribution Channel, 2019-2027
Figure 54: Global Dyslipidemia Drugs Market Share Analysis, by Company, 2018